Dr Reddy’s Laboratories (DRL) has launched Eszopiclone tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration (US FDA).
The Lunesta (eszopiclone) tablets C-IV brand and generic combined had US sales of approximately $887 million MAT for the most recent twelve months ending in January 2014 according to IMS Health. Dr Reddy’s Eszopiclone tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.
EP News Bureau – Mumbai
- Advertisement -
